<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="41390">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02567552</url>
  </required_header>
  <id_info>
    <org_study_id>1412-BCN-087-AB</org_study_id>
    <secondary_id>2015-000290-12</secondary_id>
    <nct_id>NCT02567552</nct_id>
  </id_info>
  <brief_title>Clinical Trial Comparing Endometrial Transformation With Subcutaneous Progesterone Versus Intramuscular Progesterone</brief_title>
  <official_title>Randomized Clinical Trial Comparing Endometrial Transformation With Subcutaneous Progesterone (Prolutex) 25 mg/Day Versus Intramuscular Progesterone (Prontogest) 50 mg/Day</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IVI Barcelona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IVI Barcelona</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study the endometrial predecidualization by using subcutaneous progesterone 25 mg/day versus
      intramuscular progesterone 50 mg/day, to determine whether there are differences in the
      endometrial transformation and endometrial receptivity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to compare predecidualization and endometrial receptivity as gene
      expression by using subcutaneous progesterone 25 mg/day versus intramuscular progesterone 50
      mg/day in healthy women of childbearing age. Both, the two drugs and the doses administered
      in this clinical trial, are routine clinical practice.

      A controlled ovarian stimulation will be previously performed and following routine clinical
      practice for 10-12 days at standard doses of subcutaneous FSH 150-225 IU/day, according to
      BMI and number of antral follicles. A GnRH antagonist shall be administered, being initiated
      according to donor's follicular growth from greater or equal14 mm diameter follicles. Final
      maturation shall be performed with a bolus of GnRH agonist when there exist at least 3
      follicles greater or equal17 mm diameter, and therefore performing follicular puncture 36
      hours after the bolus of agonist has been administered.

      If the donor meets the inclusion criteria, she will be informed of the study and, if she
      agrees, she will sign the informed consent. Randomization shall be performed in 2 arms; arm
      1 will be administered subcutaneous progesterone 25 mg/day (Prolutex; Angelini, Spain), and
      arm 2, intramuscular progesterone 50 mg/day (Prontogest IBSA, Italy). In each arm 12 donors
      (ITT population) will be included.

      The randomization to a treatment group shall be performed the day the follicular puncture
      has been programmed. To that purpose, a randomized consecutive sampling will be used by
      means of assignment tables. The medication will be administered by a person not involved in
      the assessments and responsible for group assignment, data centralization and drug
      assignment.

      At day 5 (5 days after follicular puncture):endometrial thickness measurement by means of
      transvaginal ultrasound and perform endometrial biopsy and take two samples: 1 sample to
      Anatomical Pathology and 1 sample to Endometrial Receptivity Array (ERA).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endometrial predecidualización</measure>
    <time_frame>5 days</time_frame>
    <description>Endometrial transformation after treatment according to criteria of Noyes et al.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Endometrial receptivity</measure>
    <time_frame>5 days</time_frame>
    <description>Endometrial receptivity according to gene expression profile (Endometrial Receptivity Array or ERA)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endometrial thickness</measure>
    <time_frame>5 days</time_frame>
    <description>Endometrial thickness measurement by means of transvaginal ultrasound.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood estradiol level</measure>
    <time_frame>day 0</time_frame>
    <description>Blood estradiol level on the day of follicular puncture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood progesterone level</measure>
    <time_frame>day 0</time_frame>
    <description>Blood progesterone level on the day of follicular puncture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood LH level</measure>
    <time_frame>day 0</time_frame>
    <description>Blood Luteinizing hormone level on the day of follicular puncture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood estradiol level</measure>
    <time_frame>5 days</time_frame>
    <description>Blood estradiol level 5 days after progesterone treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood progesterone level</measure>
    <time_frame>5 days</time_frame>
    <description>Blood progesterone level 5 days after progesterone treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood LH level</measure>
    <time_frame>5 days</time_frame>
    <description>Blood Luteinizing hormone level 5 days after progesterone treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>occurrence of side effects</measure>
    <time_frame>5 days</time_frame>
    <description>occurrence of side effects</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Reproductive Techniques, Assisted</condition>
  <arm_group>
    <arm_group_label>Prolutex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous progesterone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prontogest</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intramuscular progesterone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Subcutaneous progesterone</intervention_name>
    <description>subcutaneous progesterone 25 mg/day</description>
    <arm_group_label>Prolutex</arm_group_label>
    <other_name>Prolutex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intramuscular progesterone</intervention_name>
    <description>intramuscular progesterone 50 mg/day</description>
    <arm_group_label>Prontogest</arm_group_label>
    <other_name>Prontogest</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female aged between 18 and 34 years

          -  BMI between 18 and 28 kg/m2

          -  Endometrial thickness &gt; 7 mm the day of progesterone treatment initiation (day of
             follicular puncture)

          -  Follicular maturation with a single bolus of GnRH agonist

          -  Egg donors who undergo a cycle of ovarian stimulation in the IVI Barcelona Centre

          -  Egg donors selected in accordance with the requirements of Law 14/2006 of 26 May 2006
             on Assisted Human Reproduction Techniques

          -  Informed consent has been signed and dated

        Exclusion Criteria:

          -  Known allergy to progesterone formulations or their excipients

          -  Known allergy to estrogens

          -  Known thrombophilias

          -  Alcohol, drug or psychotropic medication dependence

          -  Concurrent participation in another study

          -  Concomitant medication that may interfere with the study medication and ovarian
             stimulation

          -  Failure to comply with the requirements for egg donors in accordance with Law 14/2006
             of 26 May 2006 on Assisted Human Reproduction Techniques
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>34 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Agustín B Boluda</last_name>
    <role>Principal Investigator</role>
    <affiliation>IVI Barcelona</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Evelin L Molina</last_name>
    <phone>935 316 301</phone>
    <email>evelin.lara@ivi.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>IVI Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08017</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evelin L Molina</last_name>
      <phone>935 316 301</phone>
      <email>evelin.lara@ivi.es</email>
    </contact>
    <investigator>
      <last_name>Agustín B Boluda</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Evelin L Molina</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ana Belén C Balazote</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Verónica G Martínez</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <lastchanged_date>October 2, 2015</lastchanged_date>
  <firstreceived_date>October 2, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>endometrial receptivity</keyword>
  <keyword>endometrial predecidualization</keyword>
  <keyword>endometrial genomics</keyword>
  <keyword>endometrial receptivity array</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
